CHICAGO, Nov. 4 (UPI) -- Prevnar, the popular drug to prevent bacterial meningitis, is on course to make more than $1 billion this year, a report says.
Sales of Prevnar, made by the pharmaceutical giant Wyeth, soared 32 percent in the third quarter to $321 million, the Chicago Tribune said Thursday.
A recent financial statement indicated this came about in part because the company made upgrades and improvements to its manufacturing facilities over the last year.
Prevnar vaccine costs about $260 for the four-shot regimen given to infants and young children. A dose of flu vaccine, by contrast, fetches about $8.
Wyeth left the flu vaccine market entirely last year to focus resources on its more lucrative vaccine.